Logo
x

Search

Subscribe Now

Renal Cell Carcinoma

Merck’s Keytruda + Lenvima Receives MHLW’s Approval in Japan to Treat Renal Cell Carcinoma

Merck’s Keytruda + Lenvima Receives MHLW’s Approval in Japan to Treat Renal Cell Carcinoma

  • February 28, 2022
Merck's Keytruda (pembrolizumab) Receives the US FDA's Approval as an Adjuvant Therapy for Renal Cell Carcinoma

Merck's Keytruda (pembrolizumab) Receives the US FDA's Approval as an Adjuvant Therapy for Renal Cell Carcinoma

  • November 19, 2021
BMS Reports Five-Year Data of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-III CheckMate -214 for the Treatment of Advanced or Metastatic Renal Cell Carcinoma

BMS Reports Five-Year Data of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-III CheckMate -214 for the Treatment of Advanced or Me...

  • September 16, 2021
Takeda and Ono's Opdivo (nivolumab) + Cabometyx (cabozantinib) Receive MHLW's Approval for the Treatment of Unresectable or Metastatic Renal Cell Carcinoma

Takeda and Ono's Opdivo (nivolumab) + Cabometyx (cabozantinib) Receive MHLW's Approval for the Treatment of Unresectable or Metast...

  • August 25, 2021
Merck Presents Results of Keytruda (pembrolizumab) in P-III KEYNOTE-564 as Adjuvant Therapy for Renal Cell Carcinoma at ASC0 2021

Merck Presents Results of Keytruda (pembrolizumab) in P-III KEYNOTE-564 as Adjuvant Therapy for Renal Cell Carcinoma at ASC0 2021

  • June 4, 2021
BMS' Opdivo (nivolumab) + Cabometyx (cabozantinib) Receive EC's Approval for 1L Treatment of Advanced Renal Cell Carcinoma

BMS' Opdivo (nivolumab) + Cabometyx (cabozantinib) Receive EC's Approval for 1L Treatment of Advanced Renal Cell Carcinoma

  • April 15, 2021
BMS Reports the US FDA’s Acceptance of BLA for Opdivo to Treat Clear Cell Renal Cell Carcinoma

    BMS Reports the US FDA’s Acceptance of BLA for Opdivo to Treat Clear Cell Renal Cell Carcinoma

    • May 6, 2024
    BMS Reports 4-Year Follow-Up Data for Opdivo with Cabometyx in P-III Trial to Treat Advanced Renal Cell Carcinoma (RCC)

      BMS Reports 4-Year Follow-Up Data for Opdivo with Cabometyx in P-III Trial to Treat Advanced Renal Cell Carcinoma (RCC)

      • January 23, 2024
      Johnson & Johnson Acquires Ambrx Biopharma for ~$2.0B

        Johnson & Johnson Acquires Ambrx Biopharma for ~$2.0B

        • January 9, 2024
        Merck & Co. Receives the US FDA’s Approval for Welireg (belzutifan) to Treat Advanced Renal Cell Carcinoma (RCC)

          Merck & Co. Receives the US FDA’s Approval for Welireg (belzutifan) to Treat Advanced Renal Cell Carcinoma (RCC)

          • December 15, 2023
          Hutchmed Completes Enrollment for the P-II/III Trial for Fruquintinib + Sintilimab to Treat Renal Cell Carcinoma in China

            Hutchmed Completes Enrollment for the P-II/III Trial for Fruquintinib + Sintilimab to Treat Renal Cell Carcinoma in China

            • December 13, 2023
            Merck’s P-III Trial Assessing Keytruda Met its Secondary Endpoint in Renal Cell Carcinoma (RCC) Patients

              Merck’s P-III Trial Assessing Keytruda Met its Secondary Endpoint in Renal Cell Carcinoma (RCC) Patients

              • November 2, 2023
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.